^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FCN-411

    i
    Other names: FCN-411
    Company:
    Fosun Pharma
    Drug class:
    pan-HER inhibitor
    Related drugs:
    over2years
    A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. (PubMed, Lung Cancer)
    FCN-411 was well tolerated and demonstrated preliminary antitumor activity in patients with EGFR-mutated NSCLC after progression on EGFR-TKIs, especially in those without EGFR T790M mutation. The RP2D was defined as 8 mg once daily. Future studies are warranted.
    P1 data • Clinical Trial,Phase I • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    EGFR mutation • EGFR T790M • EGFR exon 18 mutation
    |
    FCN-411
    over4years
    A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation (clinicaltrials.gov)
    P1, N=66, Recruiting, Ahon Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Jun 2018 --> Dec 2020
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    FCN-411
    almost6years
    A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, Ahon Pharmaceutical Co., Ltd.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    FCN-411